Genetic and biochemical abnormalities of a-synuclein (a-Syn) are directly implicated in the pathogenesis of familial and sporadic forms of Parkinson's disease (PD). We have show that transgenic (Tg) mice expressing the A53T mutant oc-Syn, but not wild type (WT) or A30P, develop adult-onset disease with a progressive motor dysfunction, shortened life-span, and pathological features of human a-synucleinopathies. The studies of these mice and the cell lines expressing a-Syn have allowed us to identify potentially pathogenic biochemical alterations of a-Syn. Specifically, the disease in Tg mice is associated with the increase levels of detergent insoluble a-Syn aggregates and the accumulation of potentially pathogenic soluble oligomers. Our studies show that a-Syn is normally proteolytically truncated at the Carboxy-terminal region to generate a-Syn(AC)s. Correlative studies in human tissues, cell lines, and in vitro aggregation studies support the view that a-Syn(AC)s promotes the pathological aggregation of a-Syn. Our results also show that differential stabilization of a-Syn polypeptides may modulate vulnerability to a-synucleinopathies. Thus, factors that affect a-Syn metabolism modulate the vulnerability of selected neuronal populations to a-synucleinopathies in humans and in mice. In this proposal, we will explore the relationships between a-Syn metabolism/truncation and aggregation/oligomerization of a-Syn. To better define the relationships between of a-Syn metabolism, a-Syn aggregation and a-synucleinopathies, we propose following Aims. 1) Characterize proteolytic truncations of a-Syn and a-synucleinopathy-associated alterations of a-Syn in human and mouse. 2) Characterize the aggregation and oligomerization properties of truncated a-Syn variants using in vitro and in cell culture systems. 3) Characterize the primary sequence determinants and the cell biology of a-Syn metabolism/truncations. 4) Determine whether the known proteolytic systems are responsible for a-Syn metabolism/truncation in neuronal cells.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS038065-09
Application #
7595178
Study Section
Special Emphasis Panel (ZRG1-CDIN (01))
Program Officer
Sutherland, Margaret L
Project Start
1998-12-15
Project End
2009-05-31
Budget Start
2009-04-01
Budget End
2009-05-31
Support Year
9
Fiscal Year
2009
Total Cost
$359,598
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Daher, João Paulo L; Pletnikova, Olga; Biskup, Saskia et al. (2012) Neurodegenerative phenotypes in an A53T ?-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet 21:2420-31
Tuite, Paul J; Mangia, Silvia; Tyan, Andrew E et al. (2012) Magnetization transfer and adiabatic R 1? MRI in the brainstem of Parkinson's disease. Parkinsonism Relat Disord 18:623-5
Colla, Emanuela; Jensen, Poul H; Pletnikova, Olga et al. (2012) Accumulation of toxic ?-synuclein oligomer within endoplasmic reticulum occurs in ?-synucleinopathy in vivo. J Neurosci 32:3301-5
Colla, Emanuela; Coune, Philippe; Liu, Ying et al. (2012) Endoplasmic reticulum stress is important for the manifestations of ?-synucleinopathy in vivo. J Neurosci 32:3306-20
Thomas, Bobby; Mandir, Allen S; West, Neva et al. (2011) Resistance to MPTP-neurotoxicity in ?-synuclein knockout mice is complemented by human ?-synuclein and associated with increased ?-synuclein and Akt activation. PLoS One 6:e16706
Liu, Ying; Lee, Michael K; James, Maria M et al. (2011) Passive (amyloid-*) immunotherapy attenuates monoaminergic axonal degeneration in the A*PPswe/PS1dE9 mice. J Alzheimers Dis 23:271-9
Yang, Qian; She, Hua; Gearing, Marla et al. (2009) Regulation of neuronal survival factor MEF2D by chaperone-mediated autophagy. Science 323:124-7
Wang, Jiou; Martin, Elizabeth; Gonzales, Victoria et al. (2008) Differential regulation of small heat shock proteins in transgenic mouse models of neurodegenerative diseases. Neurobiol Aging 29:586-97